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ABSTRACT The PRNP gene, encoding the amyloid pre-
cursor protein that is centrally involved in Creutzfeldt-Jakob
disease (CJD), has an unstable region of five variant tandem
octapeptide coding repeats between codons 51 and 91. We
screened a total of 535 individuals for the presence of extra
repeats in this region, including patients with sporadic and
familial forms ofspongiform encephalopathy, members oftheir
families, other neurological and non-neurological patients, and
normal controls. We identified three CJD families (in each of
whicsk the- proband's disease was neuropathologically con-
firmed and experimentally transmitted to primates) that were
heterozygous for alleles with 10, 12, or 13 repeats, some of
which had "wobble" nucleotide substitutions. We also found
one individual with 9 repeats and no nucleotide substitutions
who had no evidence of neurological disease. These observa-
tions, together with data on published British patients with 11
and 14 repeats, strongly suggest that the occurrence of 10 or
more octapeptide repeats in the encoded amyloid precursor
protein predisposes to CJD.
Creutzfeldt-Jakob disease (CJD) is a subacute mental and
neurological disorder with a prominent dementia and move-
ment abnormalities typically affecting middle-aged individu-
als and leading to death in 3-12 months after the onset of
symptoms. The disease is randomly distributed in the world
with an annual mortality rate of one per million people and in
5-10% of cases shows an autosomal dominant pattern of
inheritance (1, 2). A human gene (PRNP) on the short arm of
chromosome 20 (3) codes for the precursor of the amyloid
protein (PrP, also known as "prion protein") that accumu-
lates in the brains of diseased individuals, and several dif-
ferent point and insertion mutations in this gene have been
shown to be linked to familial cases of transmissible spongi-
form encephalopathy (4, 5).
The first genetic abnormality described in CJD was an
insert of six extra 24-nucleotide repeats in the area coding for
tandem octapeptides near the N-terminal region of the PrP
molecule (6, 7). A variable number of these repeats (five or
six) also occurs in the bovine PrP gene (8). On the basis of
newly available data, we suggest that the occurrence of 10 or
more octapeptide coding repeats with irregular point substi-
tutions is a predisposing cause of familial CJD.
MATERIALS AND METHODS
The Tested Population. A total of 535 individuals were
screened for extra repeats in the PRNP gene: 117 patients
with spongiform encephalopathies (including 60 familial cas-
es); 159 first-degree relatives of patients with familial spongi-
form encephalopathies; 39 patients with other neurological
diseases; 16 patients with non-neurological diseases; and 204
normal controls.
The American family "Kel" has a father and son with CJD
ofwhom we tested only the proband (son) for mutations in the
PRNP gene. The American family "Ald" (9) has five affected
members, ofwhom we tested the proband, her sister, and all
five of her daughters from two marriages (two affected and
three unaffected). The French family "Che" has nine pa-
tients with CJD (10-12), ofwhom we tested the proband and
two unaffected at-risk daughters ofhis brother (who also died
of CJD).
DNA Samples. DNA was extracted from the frozen brain
tissue or frozen blood of the deceased patients and from fresh
or frozen anticoagulated blood of the living CJD patients,
unaffected family members, and control individuals.
Amplification, Subcloning, and Sequencing of the PRNP
Coding Region. For easier sequencing of the PRNP coding
region, we modified the technique described earlier (13, 14)
by amplifying two overlapping fragments from this region.
Both fragments were amplified from the genomic DNA by
using the polymerase chain reaction (PCR; ref. 15) with Taq
polymerase (Perkin-Elmer). The oligonucleotide primers
used to produce the 5' fragment, 5'-TACTGAGCGGC-
CGCGCAGTCATTATGGCGAACCTTG-3' and 5'-TACT-
GAGTCGACAATGTATGATGGGCCTGCTCA-3', were
composed of6 random nucleotides followed by Not I and Sal
I restriction sites, respectively, and 21 or 22 nucleotides of
the ends of the Northern fragment. To produce the 3'
fragment of the PRNP coding region we used oligonucleo-
tides 5'-TACTGAGCGGCCGCCAACATGAAGCACATG-
GCTGGT-3' and 5'-TACTGAGTCGACCCTTCCTCATC-
CCACTATCAGG-3', composed in the same fashion. The
PCR-amplified fragments were cleaved with Not I and Sal I
restriction endonucleases and ligated into pGEM-5Zf(+)
plasmid with T4 DNA ligase (Promega). The recombinant
plasmid was then transfected into DH5a competent Esche-
richia coli cells (GIBCO/BRL), which were subsequently
grown on LB agar with ampicillin (100 pg/ml). Colonies
containing the recombinant plasmids were selected and se-
Abbreviations: CJD, Creutzfeldt-Jakob disease; GSS, Gerstmann-
Straussler-Scheinker syndrome; PrP, amyloid precursor protein.
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Normal (regular) sequence
codon 61
CCT CAG GGC GGT GGT GGC TGG GGG CAG RI
pro gin gly gly gly gly trp gly gln
CCT CAT GGT GGT GGC TGG GGG CAG R2
pro his gly gly gly trp gly gln
CCT CAT GGT GGT GGC TGG GGG CAG R2
pro his gly gly gly trp gly gln
CCC CAT GGT GGT GGC TGG GGA CAG R3
pro his gly gly gly trp gly gln
CCT CAT GGT GGT GGC TGG GGT CAA R4
pro his gly gly gly trp gly gin
codon 91
Abnormal (irregular) sequences
CCT CAT GGT GGT GGC TGG GG_& CAG
pro his gly gly gly trp gly gln
CCT CAT GGC GGT GGC TGG GGG CAG
pro his gly gly gly trp gly gln
CCC CAT GGT GOT GGC TGG GGf CAG




FIG. 1. Nucleotide sequence of codons 51-91 in normal healthy
people and irregular sequences in CJD patients.
quenced in both directions by the dideoxy chain-termination
method (16) using an automated sequencer (Applied Biosys-
tems) (17). Complete sequencing of the PRNP coding region
was performed with DNA from five CJD patients, one
unaffected family member, and a control individual.
Visualization of the 5' Fragments. The 5' fragment of the
PRNP gene from individuals with various numbers of extra
repeats was PCR-amplified, as indicated in the previous
section, and electrophoresed in a horizontal 3% NuSieve plus
1% SeaKem agarose gel (FMC). DNA was stained with
ethidium bromide (0.5 ,ug/ml).
Experimental Transmission Studies. Healthy adult primates
were inoculated intracerebrally with 0.1 ml of 5% or 10%
saline suspensions of brain tissue from the neuropathologi-
cally verified probands in all three families. The tissue from
the Kel family proband was inoculated into a squirrel monkey
and a spider monkey. The tissue from the Ald family proband
was inoculated into a chimpanzee, a squirrel monkey, and a
capuchin monkey. The tissue from the Che family proband
was inoculated into a chimpanzee and a stumptail monkey.
All dying animals were sacrificed when in a terminal state of
illness, and their brains were examined histologically for
evidence of spongiform encephalopathy.
RESULTS
Normal Structure of the Repeat Region in the PRNP Gene.
In 99% of our collection of 535 genetically tested individuals,
the repeat region started at codon 51 and extended to codon
91, consisting of the five repeating structural elements shown
in Fig. 1. An initial 27-nucleotide sequence, designated R1
(11), with an additional glycine codon, and a CAT-to-CAG
substitution at.the second codon that converts glutamine to
histidine, is followed by four 24-nucleotide sequences. The
second and third repeats, designated R2 (11), are identical,
and they differ from the fourth repeat element, designated
R3, by substitutions in positions 3 (T to C) and 21 (G to A).
The fifth repeat, R4, is similar to R2, with a substitution at
position 24 (G to A).
Nine Repeats. One of the control patients (Hay) died at age
63 of advanced micronodular cirrhosis. This individual had
no family history of neurological disease and no clinical or
pathological signs of spongiform encephalopathy, and brain
tissue did not transmit disease to experimental primates. The
open reading frame of the PRNP gene was completely
sequenced, and instead of the usual five octamer repeats,
nine repeats were found (Table 1). No irregular nucleotide
substitutions occurred anywhere in the sequence.
Ten Repeats. Ten repeats were present in the proband of
the American Kel family. The sixth repeat had an irregular
single-nucleotide change from A to G at the 21st position,
which we designate R3g because the start resembles R3. This
substitution does not change the encoded amino acid.
Twelve Repeats. The affected members of the American
family Ald showed 12 repeats, identical in all three tested
patients. Two ofthe repeats were irregular: the 3rd repeat had
a T-to-C substitution at the 9th position (R2c), and the 10th
repeat had an A-to-G substitution at the 21st position, iden-
tical to that of the Kel family (R3g). Neither substitution
changes the encoded amino acid. Four unaffected members
of the family had a normal five-repeat pattern on both alleles.
Thirteen Repeats. The proband and his presently healthy
niece in the French Che family showed an identical pattern of
13 repeats. The 12th repeat (which is designated R2a) had a
G-to-A substitution at position 21. The other niece was
normal.
Fig. 2 shows the PCR-amplified 5' fragment of the PRNP
coding region in individuals with 5, 10, 12, and 13 repeats.
Phenotype Expression. Individuals with 5 and 9 repeats
showed no signs of CJD. The occurrence of 10, 12, and 13
repeats was associated with CJD or a mixed picture of CJD
and GSS, for which the clinical and pathological features are
summarized in Table 2.
Experimental Transmission. Inoculated brain suspension
from the proband of the Kel family transmitted spongiform
encephalopathy to a squirrel monkey (43-month incubation
period, 3-week illness) and a spider monkey (31-month in-
cubation period, 2 -month illness). Brain suspension from the
proband of the Ald family transmitted spongiform encepha-
lopathy to a chimpanzee (13-month incubation period,
1-month illness), a capuchin monkey (35-month incubation
period, 3-month illness), and a squirrel monkey (24-month
incubation period, 2-week illness). Brain suspension from the
proband of the Che family transmitted spongiform encepha-
lopathy to a chimpanzee (13-month incubation period,
4-month illness). A stumptail monkey inoculated at the same
time died of a non-neurological illness after an observation
period of 11 years; microscopic examination showed that the
brain was normal.
Table 1. Octapeptide coding repeats in the PRNP gene found in normal or non-CJD individuals
and in familial CJD or Gerstmann-Strdussler-Scheinker syndrome (GSS) patients
Number of Medical
repeats Family condition Order of repeats
5 Normal R1, R2, R2, R3, R4
9 Hay Cirrhosis R1, R2, R2, R3, R2, R3, R2, R3, R4
10 Kel CJD R1, R2, R2, R3, R2, R3g, R2, R2, R3, R4
11 A CJD R1, R2, R2, R2, R3, R2, R3g, R2, R2, R3, R4
12 Ald CJD R1, R2, R2c, R3, R2, R3, R2, R3, R2, R3g, R3, R4
13 Che CJD/GSS R1, R2, R2, R3, R2, R2, R2, R2, R2, R2, R2, R2a, R4
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FIG. 2. Ethidium bromide-stained fragments of the amplified 5'
portion of the PRNP coding region in normal control individual with
5 repeats (lane 1); proband Kel, with 10 repeats (lane 2); proband and
two affected daughters from the Ald family, with 12 repeats (lanes
3-5); proband and at-risk niece from the Che family, with 13 repeats
(lanes 6 and 7). The control individual shows only the normal
443-base-pair fragment; individuals heterozygous for alleles with 10,
12, and 13 repeats show additional fragment of 563, 611, and 635 base
pairs, respectively.
The range of susceptible primate species, incubation pe-
riods, and durations of illness in these inoculated animals did
not differ from those seen after inoculation of tissue from
sporadic cases of CJD.
DISCUSSION
In contrast to sporadic CJD, in which no disease-specific
mutations in thePRNP gene have yet been identified, familial
forms of spongiform encephalopathy are being linked to a
growing variety of point and insertion mutations in this gene.
Most of these mutations appear to influence the clinical
expression of disease, particularly with respect to the age at
onset and the duration of illness, but also to some extent the
clinical presentation and evolution of symptoms. For exam-
ple, point mutations in codons 102 (18-20), 117 (21-23), and
198 (24) are associated with the distinctive clinical and
pathological features of GSS, whereas point mutations in
codons 178 and 200 are associated with illnesses that in most
respects are typical of sporadic CJD, except for their com-
paratively early onset and long duration, and in the case ofthe
codon 178 mutation, the absence of periodic electroenceph-
alographic activity (25, 26).
Almost all of the familial patients with insertion mutations
that we describe in this report had exceptionally prolonged
illnesses (average of 7 years) beginning at a comparatively
early age (average of 38 years) and characterized by progres-
sive dementia accompanied by cerebellar and other neuro-
logical signs. Affected members in the English kindred with
11 repeats, first reported by Owen et al. (6, 7), and additional
patients with 11 and 14 repeats subsequently reported by the
same group (27-29) have also experienced prolonged ill-
nesses (5-12 years) beginning at a very early age (22-28
years).
The genetic mechanism for the generation of extra repeats
is probably unequal crossover. Fig. 3 illustrates a hypothet-
ical scheme for generating a variable number of repeats by
such a mechanism. The similarity of the repeats allows
limited frameshifting in the process of duplication; recombi-
nation can happen at any site. The result of the first event
could be a 7-repeat allele, which has not so far been observed.
The result ofthe second event could be the 9-repeat allele that
was observed in the control patient Hay, and further cross-
over events could result in alleles with 10 or more repetitions.
The irregular elements R3g (Kel and Ald families) and R2a
(Che family) could have been generated by a recombination
inside the R1, R2, and R3 repeats. Thus, all the observed
repetitions, including the 11-repeat insert described in the
English family (7), can be accounted for by unequal crossover
and recombination, except for the R2c repeat in the Ald
family, which may represent an independent point mutation.
Table 2. Summary of the clinical, neuropathological, and transmissible features of three families with 10, 12, or 13 octapeptide
coding repeats
Sex/age Duration Electro-
Family at onset of illness Clinical evolution encephalogram Neuropathology Transmission
Kel M/31 15 yr Progressive dementia, abnormal Diffuse slowing Spongiosis, gliosis, Squirrel and
(proband) behavior, cerebellar signs, neuronal loss spider monkeys
tremor, rigidity, myoclonus
M/45 5 yr Progressive dementia, mood change, Not recorded Spongiosis, gliosis, Not inoculated
disorientation, cerebellar signs, neuronal loss
tremor, hyper-reflexia
Ald F/31 11 yr Mood change, indifference, Diffuse slowing Spongiosis, gliosis, Chimpanzee; squirrel
(proband) confusion, aphasia, cerebellar neuronal loss and capuchin
signs, invol. movements, rigidity monkeys
F/23 10 yr Abnormal behavior, cerebellar Diffuse slowing Mild gliosis and neuronal Not inoculated
signs, mutism, rigidity, dementia, loss (no spongiosis)
myoclonus
F/35 >13 yr Clumsiness, dysphasia, cerebellar Slow-wave No biopsy or autopsy Not inoculated
(alive) signs, euphoria, dementia, burst suppression (patient still alive)
myoclonus
Che M/35 3 mo Abnormal behavior, cerebellar Periodic 1- to 2-Hz Spongiosis, gliosis, Chimpanzee
(proband) signs, mutism, pyramidal signs, triphasic neuronal loss,
hyper-reflexia, myoclonus complexes multicentric (GSS)
cerebellar plaques
M/55 1 yr Abnormal behavior, cerebellar Not recorded Spongiosis, gliosis, Not inoculated
signs, mutism, rigidity, myoclonus neuronal loss,
multicentric (GSS)
cerebellar plaques
M/43 5 yr Intellectual slowing, tremor, Slow-wave No autopsy Not inoculated
hypertonus, cerebellar signs, burst suppression
myoclonus
M/48 3 yr Intellectual slowing, decreased Diffuse slowing No autopsy Not inoculated
vision, tremor, cerebellar signs,
seizures, myoclonus
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Two normal alleles crossing over with a shift:
Ri R 2R3 R4
R1 R2 R2 R3 R4
The resulting 7-repeat allele crossing over with a normal allele:
R1 R2 R2 R3 R2 R3 R4
R1 R2 R2 R3 R4
The resulting 9-repeat allele observed in a control individual crossing
over with a normal allele, but recombination happens inside R3 and
R1 repeats:
R1 R2 R2 R3 R2 ,ARza2aR3 R4
R2 R2 R3 R4
or, in detail,
CCC CAT GGT GGT GG TGG GGA CAG
CCT CAG GGC GGT GGT GG GG GGG CAG
resulting in an irregular element




and a 10-repeat allele as observed in patient Kel:
R1 R2 R2 R3 R2 R3g R2 R2 R3 R4
FIG. 3. Likely mechanisms of generation of extra repeats.
A number of structural proteins, including collagen (30),
silk fibroin (31), keratin (32), and elastin (33, 34), contain
large numbers of repeats of from 2 to 6 amino acids, none of
which closely resembles the PrP repeat region. However,
there are three other proteins containing consecutive repeats
of a heptapeptide or octapeptide whose structure and func-
tion may give some insight into variations in the CJD amyloid
precursor structure. The maize ribosomal protein S18 has a
7-fold heptapeptide repeat at its N terminus that is thought to
have some role in RNA binding (35). The DNA-dependent
RNA polymerase II contains many repeats of a heptapeptide
in its C-terminal domain, where a regular spacing of proline
residues appears to be important in maintaining its unusual
secondary structure. Although some of the repeats may be
functionally redundant (their number varies), it has been
suggested that variations in this tandem repeat structure
could act to regulate its enzymatic activity (36). Ice-
nucleation proteins also contain very large numbers of an
octapeptide, and each octapeptide seems to contribute more
or less individually to the nucleation process (37).
A substantial body of evidence links alterations in the PrP
structure with the occurrence of spongiform encephalopathy
in humans and animals, and insertions of variable numbers of
amino acids into human PrP adds to existing models of
conformational structure and their relation to disease and
transmissibility. The repeat region of the precursor molecule
may be involved directly in a templating mechanism whereby
the normal protein is converted posttranslationally into an
enantiomorphic form of unusual conformation (38). The
presence of extra repeats might be expected to increase the
probability of spontaneous transition to the abnormal enan-
tiomer and thereafter provide an increased concentration of
template for the conversion of further molecules.
The cis-trans isomerization of regularly spaced proline
residues could play a role in this process, or, if production of
the unusual amyloidogenic form of the precursor required
cotranslational ribosomal frameshifting events in the oc-
tapeptide region (39), the extra repeats might increase the
likelihood of their spontaneous occurrence. Moreover, ad-
jacent 24-base units within the region of the mRNA encoding
amyloid octapeptide repeats are able to fold into extraordi-
nary pseudoknot structures (40). Extra repeats might in-
crease the capability of the mRNA to form these
pseudoknots.
Whatever the mechanism by which extra repeats exert
their effect, the presence of 10 or more such elements is
associated with a spectrum of dementing illnesses that, while
usually clinically recognizable as CJD, differ from the typical
disease picture in their early age at onset and very slow
progression (only one patient had an illness lasting less than
a year). They may be characterized by the classic pathology
of either CJD or GSS or, exceptionally, by a nearly normal
microscopic appearance. Experimentally, they share the
same transmissibility characteristics as other familial and
sporadic forms of spongiform encephalopathy.
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